Skip to main content
Contact Us
Subscribe
E-Edition
94°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Amylyx Pharmaceuticals, Inc. - Common Stock
(NQ:
AMLX
)
8.430
+0.310 (+3.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amylyx Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
January 21, 2025
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 10, 2025
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 09, 2025
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
4 Analysts Assess Amylyx Pharma: What You Need To Know
December 05, 2024
Via
Benzinga
Analyst Ratings For Amylyx Pharma
July 12, 2024
Via
Benzinga
6 Analysts Assess Amylyx Pharma: What You Need To Know
June 24, 2024
Via
Benzinga
Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer
January 06, 2025
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia
December 04, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
November 27, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
May 10, 2024
Via
Benzinga
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November
November 18, 2024
Via
Benzinga
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday
November 18, 2024
Via
Benzinga
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
November 18, 2024
Via
Benzinga
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 07, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024
November 04, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Why Amylyx Pharmaceuticals Stock Was So Healthy This Week
October 18, 2024
The company seems to have a winner on its hands with a drug that targets a rare genetic disorder.
Via
The Motley Fool
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
October 17, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024
October 15, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying
September 17, 2024
Via
Benzinga
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
August 28, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration
August 12, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
August 05, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome
August 02, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday
July 12, 2024
Via
Benzinga
Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?
July 10, 2024
Amylyx Pharmaceuticals acquired avexitide from Eiger BioPharmaceuticals Inc. for $35.1 million. Avexitide, a GLP-1 receptor antagonist, ready for Phase 3 trial for post-bariatric hypoglycemia and...
Via
Benzinga
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation
July 10, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide
July 09, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Amylyx Pharmaceuticals, Inc.
Via
Business Wire
AMLX Stock Earnings: Amylyx Pharma Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
AMLX stock results show that Amylyx Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.